Table 1. Clinical characteristics of study sample 2.
| Characteristics | Women (N=1703) | Men (N=1498) |
|---|---|---|
| Age, years | 58.8±9.6 | 59.2±9.6 |
| Follow-up time, years | 12.6±2.6 | 12.0±3.3 |
| Body mass index, kg/m2 | 27.4±5.7 | 28.7±4.4 |
| Total cholesterol, mg/dl | 212.0±38.3 | 198.3±36.0 |
| HDL cholesterol, mg/dl | 57.9±16.0 | 43.3±11.9 |
| Lipid lowering medication (%) | 10.9 | 16.3 |
| Fasting glucose, mg/dL | 100.2±26.7 | 107.5±28.3 |
| Diabetes (%) | 7.6 | 11.9 |
| Diabetes medication (%) | 3.8 | 6.5 |
| Systolic blood pressure, mm Hg | 127.0±20.1 | 129.7±17.0 |
| Diastolic blood pressure, mm Hg | 73.9±9.3 | 77.4±9.4 |
| Hypertensive (%) | 66.8 | 77.4 |
| Antihypertensive medication (%) | 25.0 | 30.6 |
| Smokers (%) | 14.9 | 14.2 |
| Diet score | 1.7±0.9 | 1.4±0.9 |
| Physical activity score | 33.8±5.1 | 36.4±7.3 |
| Biomarkers*, median (Q1, Q3) | ||
| B-type natriuretic peptide, pg/mL | 9.8 (4.0, 19.6) | 6.3 (4.0, 15.9) |
| Urine albumin-to-Cr ratio, μg/mg | 8.5 (3.5, 17.3) | 4.8 (2.0, 10.6) |
| CVH score (mean±SD) | 8.7±2.2 | 8.4±2.0 |
HDL indicates high-density lipoprotein; Q1, quartile 1; Q3, quartile 3; Cr, creatinine; CVH, cardiovascular health.
*
Sample size for the biomarker evaluation was 2046.